1. How many patients in the last 12 months has the trust treated for metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia (AML)?
Metastatic Cholangiocarcinoma (CCA) – NIL
Acute Myeloid Leukaemia (AML) – 7
a. For each of AML and CCA, how many have IDH-1 mutation?
b. How many CCA are intrahepatic vs extrahepatic?
i. How many of each of these present at 2nd line? How many of these at 2nd line have IDH-1 mutation?
c. For AML, how many patients were not fit for intensive chemotherapy? How many of these AML patients have IDH-1 mutation?
The Trust cannot provide an answer to these questions as it is not recorded in the forms stated in the questions above.
2. How many patients have been treated with pemigatinib (CCA), venetoclax plus azacitadine dual therapy or azacitadine monotherapy (AML )?
Pemigatinib – NIL
Venetoclax + Azacitadine – < 5
Azacitidine monotherapy – < 5
a. What is the average treatment duration for CCA patients treated with pemigatinib and AML patients treated with azacitadine dual therapy and azacitadine monotherapy?
The Trust cannot provide a response to this question as there is not enough information recorded to provide an average.
b. What is the preferred azacitadine product?
The product given is dependent on the current contract in place
3. What is the real-world dosing for venetoclax (in combination with a CYP3A4)?
This information is not recorded within our systems
a. What is the antifungal of choice for patients treated with venetoclax?
Posaconazole
b. What is the antifungal average treatment duration when used in combination with venetoclax?
Not all indications receive an antifungal treatment. Where it is uses it is prophylactic throughout treatment or added after an active fungal infection.
c. What proportion of patients are treated with an antifungal in combination with venetoclax? In what proportion of patients is the antifungal treatment stopped? In what proportion of these pts is the venetoclax dosage altered following cessation of the antifungal?
Unfortunately, the systems used by the Trust do not record the requested information in an accurate format that is easily accessible. The Trust does not currently have an Electronic Patient Record and to retrieve this information would require a manual trawl of all patient case notes which would take in excess of 18 hours. In accordance with Section 12(1) of the Freedom of Information Act 2000, the Trust is therefore not obliged to proceed with this request
4. Do you routinely test CCA and AML patients for IDH-1 mutation? No We do not test routinely for AML patients
a. If so when does the testing take place. E.g. at diagnosis or following 1st line progression? Is this done using NGS panel? Is this done using PCR testing? N/A
b. What is the average turnaround time for these tests? pharmacy don't routinely look for these mutations as part of clinical screening for current treatments.
5. Who is responsible for the routine management of patients with CCA and AML?
a. Clinical oncologist / medical oncologist / specialist nurse etc?
CAA – Usually solid tumour team (i.e. oncology team)
AML – Haematology team
6. How many admissions have occurred in the last 12 months for patients with CCA and AML?
a. What is their average length of stay?
b. How many of these patients were readmissions or readmitted during this time? If readmitted, can you state the main reason?
The Trust cannot provide a response to this question as it is not centrally recoded.
Over the latest 12 months of data that you have access to, how many patients who were diagnosed with HR+ adjuvant breast cancer received trastuzumab monotherapy? 22
